Prana Completes Final Patient Dosing in Alzheimer's Phase II Trial
Posted on: Wednesday, 19 December 2007, 09:00 CST
Biopharmaceutical firm Prana Biotechnology has completed final patient dosing in its double-blind, placebo-controlled Phase IIa clinical trial of PBT2 in patients with early Alzheimer's disease.
The trial was designed to explore the safety and tolerability of PBT2, and its effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer's disease as well as measures of cognition. The final follow-up visits for patients will be completed before the end of December. The company said that the trial is on track to deliver results in the first quarter of 2008.
Steven Targum, chief medical advisor to Prana, said: "We are delighted to have completed dosing of patients. Given the lack of drug-related serious adverse events and the positive independent Data Safety Monitoring Board reports, the drug has shown itself to be well tolerated. Indeed, there were no treatment-related withdrawals from the trial and a very high level of patient compliance which is also very pleasing."
Source: Datamonitor
Related Articles
- ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients With Peripheral T-Cell Lymphoma
- ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
- Thallion Completes Patient Enrollment in Phase II Trial for CAP-232
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Covalent Group, Inc. Announces $2.1 Million Contract To Conduct Patient Disease Registry In Hospitalized Subjects With Hyponatremia
- Covalent Group, Inc. And Sudler & Hennessey Announce Strategic Partnership to Design and Conduct Global Patient Disease Registries
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- Penwest Completes Patient Enrollment of Phase IIa Trial for PW4142
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds